Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
**** MARKET DOESNT CARE ABOUT THIS PR****
RELIEF HAS PURCHASED WORTHLESS COMPANIES WITH DRUGS
THAT TARGET SUCH A SMALL POPULATION THEY WILL NEVER REALLY MAKE A FISCAL DIFFERENCE!!
WITHOUT RLF-100 THIS COMPANY WILL BE WORTHLESS AND RAM/JACK AND THE REST OF RELIEF
MANAGEMENT HAS DESTROYED THIS WITH THEIR INEPTITUDE!!!! LETS HOPE THE DRUG CAN
WIN OUT THROUGH ALL THE SLIME THE SCUM MANAGEMENT AT RELIEF HAS PUT IT THROUGH!!!!
**** RELIEF MANAGEMENT IS ABYSMAL****
RAM AND JACK AND THE REST ARE WORTHLESS AND CARE NOTHING
ABOUT SHAREHOLDERS!!!! LAWSUITS WILL FOLLOW IM SURE!!!
*** THEN WHY DID DR JAVITT HAVE SLIDE....
IN HIS PRESENTATION THAT SAID ...
“EUA APPROVAL EXPECTED END OF SUMMER”
ANOTHER MISLEADING STATEMENT TO INVESTORS??
I MEAN IF HE IS IN “CONSTANT CONTACT” WITH FDA LIKE EVERYONE SAYS....
AND THEY KEEP REQUESTING MORE INFO, DO YOU THINK THEY WOULDNT HAVE TOLD
HIM THEM WANT ACTIV DATA????
ACTIV3 TRIAL COMPLETE????
DR JOEY AND SOME HERE SAYING THAT FDA WAITING TILL ACTIV 3 TRIAL DONE BEFORE EUA????
GET READY TO WAIT UNTIL AFTER THE NEW YEAR....
THAT TRIAL IS LPLV +90 DAYS (3 MONTHS)
WHY WOULD DR J THEN SAY EUA “EXPECTED BY END OF SUMMER 2021” IN CONFERENCE PRESENTATION????
ACTIV3 TRIAL COMPLETE????
DR JOEY AND SOME HERE SAYING THAT FDA WAITING TILL ACTIV 3 TRIAL DONE BEFORE EUA????
GET READY TO WAIT UNTIL AFTER THE NEW YEAR....
THAT TRIAL IS LPLV +90 DAYS (3 MONTHS)
WHY WOULD DR J THEN SAY EUA “EXPECTED BY END OF SUMMER 2021” IN CONFERENCE PRESENTATION????
Turd... you said and wrote all that...
But don’t even know it says right in the agreement that arbitration is first remedy?
**** REASON FOR DELAY.....****
Soooo considering that I was proven right (YET AGAIN) now that $NRXP themselves have verified in their newest S1 that possible litigation could halt manufacturing, distribution, and sales of ZYESAMI/AVIPTADIL.... IT IS ALSO TRUE (just like I said) THAT MAYBE THAT IS WHY FDA IS DRAGGING THEIR FEET... THEY DONT WANT TO WEAR MORE EGG ON THEIR FACES APPROVING A DRUG, TOUTING ITS AMAZING CAPABILITIES ONLY TO HAVE NO ONE BE ABLE TO GET IT BECAUSE THESE IDIOTS ARE SO GREEDY!!!!
**** REASON FOR DELAY.....****
Soooo considering that I was proven right (YET AGAIN) now that $NRXP themselves have verified in their newest S1 that possible litigation could halt manufacturing, distribution, and sales of ZYESAMI/AVIPTADIL.... IT IS ALSO TRUE (just like I said) THAT MAYBE THAT IS WHY FDA IS DRAGGING THEIR FEET... THEY DONT WANT TO WEAR MORE EGG ON THEIR FACES APPROVING A DRUG, TOUTING ITS AMAZING CAPABILITIES ONLY TO HAVE NO ONE BE ABLE TO GET IT BECAUSE THESE IDIOTS ARE SO GREEDY!!!!
***** CONGRATULATIONS DR DECEIT****
Remember 3 weeks ago (THREE <3> WEEKS!!!!!!) When they dug up and rehashed the Cardinal Health partnership and re PR’d it and everyone was sooooo sure it meant EUA APPROVAL (or “activation”) was imminent because of MISLEADING wording in it... WELL that was THREE (3) WEEKS AGO... AMD JAVITT fooled hard earned money out of people AGAIN... Now the “EUA ACTIVATION” verbiage in this “new” (rehashed) PR which this time was put out by ex NRX employee (language condoned by posting on LinkedIn).... tricked MORE money out of unsuspecting innocent people uneducated on these TRICKS!!
SEEING THE PATTERN YET????
$NRXP
MISLEADING AND SCREWING INNOCENT PEOPLE SINCE 2020 PUT YOUR HANDS TOGETHER FOR DR DECEIT!!!!
REMEMBER.... (These are all quotes) Expect a prompt response, usually within 60 days, because the regulatory agency already knows a lot about our drug, a guided missile against Covid, Aking to Penicillin!!!
NOW ITS “END OF SUMMER” never ends!!!
***** CONGRATULATIONS DR DECEIT****
Remember 3 weeks ago (THREE <3> WEEKS!!!!!!) When they dug up and rehashed the Cardinal Health partnership and re PR’d it and everyone was sooooo sure it meant EUA APPROVAL (or “activation”) was imminent because of MISLEADING wording in it... WELL that was THREE (3) WEEKS AGO... AMD JAVITT fooled hard earned money out of people AGAIN... Now the “EUA ACTIVATION” verbiage in this “new” (rehashed) PR which this time was put out by ex NRX employee (language condoned by posting on LinkedIn).... tricked MORE money out of unsuspecting innocent people uneducated on these TRICKS!!
SEEING THE PATTERN YET????
$NRXP
MISLEADING AND SCREWING INNOCENT PEOPLE SINCE 2020 PUT YOUR HANDS TOGETHER FOR DR DECEIT!!!!
REMEMBER.... (These are all quotes) Expect a prompt response, usually within 60 days, because the regulatory agency already knows a lot about our drug, a guided missile against Covid, Aking to Penicillin!!!
NOW ITS “END OF SUMMER” never ends!!!
*** RIGHT YET AGAIN... READ BELOW****
REMEMBER when everyone called me CRAZY for saying these idiots are going to fight until INJUNCTIONS are filed halting all manufacturing, production and sales... Well this is from new SEC filing... (right again)
However, trade disputes such as the interpretation of contractual obligations, payments for services, development obligations, or intellectual property ownership may arise in any joint development activity. If conflicts arise with one of our partners, that partner may act in a way that is contrary to our interests. Any such disagreement could result in one or more of the following, each of which could delay or prevent the development or commercialization of our product candidates, and in turn prevent us from generating revenue
*** RIGHT YET AGAIN... READ BELOW****
REMEMBER when everyone called me CRAZY for saying these idiots are going to fight until INJUNCTIONS are filed halting all manufacturing, production and sales... Well this is from new SEC filing... (right again)
However, trade disputes such as the interpretation of contractual obligations, payments for services, development obligations, or intellectual property ownership may arise in any joint development activity. If conflicts arise with one of our partners, that partner may act in a way that is contrary to our interests. Any such disagreement could result in one or more of the following, each of which could delay or prevent the development or commercialization of our product candidates, and in turn prevent us from generating revenue
PEGS... BECAUSE I BELIEVE IN THE DRUG.....
MANAGEMENT IS ABYSMAL ON BOTH SIDES AND THEIR FIGHTING HAS COST LIVES!!
HOPEFULLY THE DRUG CAN RISE ABOVE AND OUT OF THE FILTH THEY COVERED IT IN
SO DR DECEIT in addition to being listed author of Print that said EUA was approved in Ukraine, Caucus region and India.... also said while ringing the bell at NASDAQ... that other countries would SOON follow Georgia.... WELL yet another misleading (lie) “soon” time frame has PASSED and ZERO more approvals and ZERO orders from Georgia in fact!!! LIE AND MISLEAD MUCH??
PER SCUM.. 1/50 ADR THEN IMMEDIATE DILUTION
OF 50-100 MILLION SO THEY CAN BUY MORE WORTHLESS TRASH!!!!
OBVIOUS SIGNS OF ORCHESTRATING..... Let’s look at recent events... Javitt actively tries to IMPLODE Relief SP with statements on 9/3 (In addition time another of his patented delays).. BUT NO MEDIA REALLY RUNS THE STORY...
Then Relief Refutes Javitts statements and it DOES get Picked up and ran by major news outlets...
SOOOO What does Dr Deceit do, issues more today but this time it’s run by media, who you ask?
(Drumroll).... MARKETSCREENER.... The same MARKETSCREENER that put out the DISASTER 2/9 PR prior to anyone else CRUSHING SP which never recovered... HMMMMMM
OBVIOUS SIGNS OF ORCHESTRATING..... Let’s look at recent events... Javitt actively tries to IMPLODE Relief SP with statements on 9/3 (In addition time another of his patented delays).. BUT NO MEDIA REALLY RUNS THE STORY...
Then Relief Refutes Javitts statements and it DOES get Picked up and ran by major news outlets...
SOOOO What does Dr Deceit do, issues more today but this time it’s run by media, who you ask?
(Drumroll).... MARKETSCREENER.... The same MARKETSCREENER that put out the DISASTER 2/9 PR prior to anyone else CRUSHING SP which never recovered... HMMMMMM
SO TURDBLOSSOM.. WHY DID HE DO IT NOW!???
**** DILUTION YET AGAIN THROUGH SSF*****
312,000,000 Shares yet AGAIN!!!!
No drawdowns have been made
until September 1, 2021,resulting in a remaining balance of
the full amount under the SSF of CHF 50 million. GEM's
purchase position has been calculated using the closing
price of the registered shares of RELIEF THERAPEUTICS
Holding SA on SIX Swiss Exchange on September 1, 2021 (CHF
0.178) and applying the 10% discount agreed in the SSF
(resulting in a share price of CHF 0.1602), by dividing the
remaining balance under the SSF of CHF 50 million by such
share price of CHF 0.1602.
However, according to the
terms of the SSF, future subscription prices under the SSF
will correspond to 90% of the average of the closing bid
prices on SIX Swiss Exchange during the relevant reference
period, which corresponds to 15 trading days following
RELIEF THERAPEUTICS Holding SA's relevant subscription
request.
So Relief makes the request on Sept 1..... Then Javitt torpedos SP with his garbage on Sept 3rd... causing panic and sell off.... Gee I wonder who benefits the most if SP drops 15 days following Reliefs subscription request on Sept 1!!!!
Thanks 404!! now let’s just hope
Like I HAVE SAID ALL ALONG THAT THE DRUG CAN SHINE THROUGH ALL THE SLIME OF MANAGEMENT
**** MUST READ IMPORTANT FACT****
SAW THIS POSTED AND MAKES PERFECT SENSE...
Think about this.... Per his OWN ADMISSION.. Dr Javitt said himself that they gave the FDA the exact same data they gave the FDA.... Sooo that would mean that the FDA (originally) only got the Clinical report and thus( like relief states) the Clinical report does NOT have the Raw Data, any of the over 59,000 patient files, Or the data on the multiple statistical analysis performed..... Remember Dr Javitt KNOWS the ins and out of the FDA... So his INTENT was to not provide that info... He must have known FDA would be forced to ask for more info... SHADY!!!!
**** MUST READ IMPORTANT FACT****
SAW THIS POSTED AND MAKES PERFECT SENSE...
Think about this.... Per his OWN ADMISSION.. Dr Javitt said himself that they gave the FDA the exact same data they gave the FDA.... Sooo that would mean that the FDA (originally) only got the Clinical report and thus( like relief states) the Clinical report does NOT have the Raw Data, any of the over 59,000 patient files, Or the data on the multiple statistical analysis performed..... Remember Dr Javitt KNOWS the ins and out of the FDA... So his INTENT was to not provide that info... He must have known FDA would be forced to ask for more info... SHADY!!!!
**** VINDICATED... RIGHT ALL ALONG****
*** Proven RIGHT AGAIN****
**** JUST REMEMBER I WAS RIGHT ALL ALONG!!!*****
**** THIS IS A MUST MUST READ... WTF IS THIS?****
Our involvement with aviptadil began on March 4, 2021 when Relief Therapeutics approached our Chief Executive Officer Jonathan Javitt and asked him to develop an aviptadil formulation based on archival data, including an FDA IND license (52,088). The discovery of aviptadil (synthetic VIP) in treating lung disorders was made by Professor Said in the 1970s and was demonstrated in a Phase I clinical trial of VIP. Relief Therapeutics’ board nominated Jonathan Javitt to serve as Vice Chairman of Relief Therapeutics and voted to award Jonathan Javitt a 10% equity interest in Relief Therapeutics. The FDA rejected the use of 52,088 on the grounds that the IND was an investigator-sponsored IND owned by Stony Brook University and canceled by FDA in 2014 after the death of the IND Principal Investigator, Professor Said). No other IND for aviptadil was in force in any jurisdiction and it was learned that the predecessor of Relief Therapeutics had applied for and not been granted an IND for human use of aviptadil on multiple other occasions.
With the agreement of Relief Therapeutics, NeuroRx submitted an FDA compliant IND 149,152 to FDA on March 24, 2020 and was issued a “Study May Proceed” letter by FDA on March 28, 2020. The companies agreed to an initial framework for cooperation under which Relief Therapeutics would fund all development costs related to aviptadil and NeuroRx would be granted an additional 20% of the equity in Relief Therapeutics. This offer was submitted to us in various term sheets by the Chairman of Relief Therapeutics. Additionally, NeuroRx and Relief Therapeutics agreed to various divisions of profits from sales of aviptadil, conditional upon Relief Therapeutics’ funding of the development. Over the subsequent months, NeuroRx learned that the management of Relief Therapeutics did not have the corporate authority to issue the shares in Relief Therapeutics that had been proffered. Relief Therapeutics then proposed various business combinations under which NRx would own a majority share of the surviving corporation. Although one such combination was ratified by the boards of Relief Therapeutics and NeuroRx awarding NeuroRx 55% of the surviving corporation, the board of Relief Therapeutics never presented the agreement to the shareholders of Relief Therapeutics for consideration. Jonathan Javitt additionally requested that Relief Therapeutics update its disclosure related to the intellectual property
underlying aviptadil, which Relief Therapeutics rejected. At that point, Jonathan Javitt advised Relief Therapeutics that he would not join the board of Relief Therapeutics or to serve as the Vice Chairman of Relief Therapeutics.. (JUST LIKE I TOLD EVERYONE AND WAS CALLED CRAZY FOR!!!!)
In addition, in September 2021, NeuroRx and Relief Therapeutics agreed to collaborate as separate companies under a structure where Relief Therapeutics had the right to fund all development costs related to aviptadil for respiratory diseases in exchange for a predetermined division of profits and NeuroRx had the right to continue its development program with other investor funds should Relief Therapeutics not provide funding. The agreement recognizes ownership by NRx of all intellectual property developed by or licensed by NRx with Relief Therapeutics advised its investors in various annual reports issued in 2020 and earlier that it had formulated aviptadil as a human drug and had “1 million doses” available to treat patients. In the course of development, NeuroRx learned that there was no stable formulation of aviptadil and began developing the intravenous formulation with manufacturing records submitted to and reviewed by FDA.
We reported to Relief Therapeutics in December 2020 that the formulation data provided by Relief Therapeutics could not be replicated and that a new formulation and manufacturing method was required. Moreover, we were warned by a former Relief Therapeutics declined to fund the costs of developing a stable formulation of aviptadil, which NRx proceeded to do with funding from other investors under the tradename ZYESAMI, named for Professor Sami Said. In May 2021, Relief Therapeutics advised its shareholders that Relief Therapeutics was aware of the stability problems with its formulation at the time it signed the September 2020 collaboration agreement.
I guess I was mistaken, Javitt did not
Guarentee we will be paid
I guess I was mistaken, Javitt did not
Guarentee we will be paid
*** JAVITT GUARENTEED WE WILL BE PAID****
Guaranteeing that with patience will “pay us very well”
This is the process of FDA therapeutic drug approval. Patience is going to pay us very well.
*** JAVITT GUARENTEED WE WILL BE PAID****
Guaranteeing that with patience will “pay us very well”
This is the process of FDA therapeutic drug approval. Patience is going to pay us very well.
*** WHY NOW NRX? WHY NOT PREVIOUS FILINGS??***
Question... Reading the filing by $NRXP i noticed the dates... All happening BEFORE the SPAC merger...
If NRX knew that relief acted so egregiously, and found the need to document it in SO much detail yesterday... Shouldnt they have documented it the same way PRIOR to completion of merger, for full disclosure to shareholders??
Seems like withholding of material information.. I don’t remember seeing the Bachem Fraud claim in Pre merger SEC filing and that happened pre merger.. I don’t remember seeing most/all of the detail we now know, but they knew then and didn’t tell shareholders/ potential investors....
wonder why? MISLEAD MUCH?? SHADY SLIME!!!!
**** WHY NOW NRX? WHY NOT PREVIOUS FILINGS??***
Question... Reading the filing by $NRXP i noticed the dates... All happening BEFORE the SPAC merger...
If NRX knew that relief acted so egregiously, and found the need to document it in SO much detail yesterday... Shouldnt they have documented it the same way PRIOR to completion of merger, for full disclosure to shareholders??
Seems like withholding of material information.. I don’t remember seeing the Bachem Fraud claim in Pre merger SEC filing and that happened pre merger.. I don’t remember seeing most/all of the detail we now know, but they knew then and didn’t tell shareholders/ potential investors....
wonder why? MISLEAD MUCH?? SHADY SLIME!!!!
PENNY.... FDA MIGHT REJECT IT BECAUSE DISPUTE
THE FDA DOESNT NEED ANOTHER BLACK EYE, APPROVE A DRUG THAT NO ONE CAN GET
BECAUSE OF INJUNCTIONS FILED STOPPING PRODUCTION/SALES UNTIL COURT CASE SETTLED
NRX planned this for holiday weekend, SIX WILL
SELL OFF HUGE ON MONDAY WHILE OUR MARKET IS CLOSED!!!
*** AFFIRMATION... LIKE IVE BEEN SAYING FOR A YEAR****
RAM JACK AND THE ENTIRE MANAGEMENT TEAM AT RELIEF ARE ABYSMAL... THEY HAVE SCREWED
OVER EVERY SINGLE SHAREHOLDER... AND IM SURE LITIGATION WILL FOLLOW... WONDER WHAT SEC
LICENSES RAM HAS? I AM SURE THE SEC AND HC WOULD LOVE TO SEE HOW THIS WAS HANDLED!!
THEY ARE SLIME!!!!*****
*** THIS PART IS THE WORST PART OF NRX FILING****
Despite Relief Therapeutics’ knowledge that it has not funded these and other areas of the collaboration agreement and despite the non-reproducible nature of the formulation and stability data Relief Therapeutics provided as part of its partnership contribution, Relief Therapeutics continues to advise its shareholders that it is entitled to the previously contemplated share of profits from intravenous and inhaled ZYESAMI™. NOTICE THAT SAYS IV AND INHALED!!!!
*** OUCH.... black and white****
As of July 31, 2021, Relief Therapeutics has not funded any costs of re-formulation of aviptadil into a shelf stable product. There is no provision in the Relief Agreement that gives Relief Therapeutics access to development assets that Relief Therapeutics has not funded, nor does Relief Therapeutics own any patents that block NRx’s development of ZYESAMI™.
Didn’t Dr J say that trial is now end of year for data?
JB.. So are you saying EUA will be denied or held off
Until NIH data proves Efficacy????
That’s mid 2022!!!
**** FEUD IS ONGOING RAM/JACK ETC ARE ABYSMAL****
As described above in the section titled “— Funding by Relief Therapeutics” and elsewhere in this prospectus, we reaffirm our commitment to honoring its collaboration agreement with Relief Therapeutics and is committed to resolving these aforementioned issues with Relief Therapeutics in an amicable manner, although these circumstances may lead to a dispute with Relief Therapeutics regarding what share of profits Relief Therapeutics should be entitled to receive based upon its reduced participation in the project. Relief Therapeutics has advised us that it desires to receive the originally-agreed share of profit despite not having funded the project and despite the non-replicable nature of the formulation data provided by Relief Therapeutics to NRx.